After coming within striking distance of its all-time high, the Dow Jones Industrial Average pulled back sharply yesterday, dropping 108 points after the Fed's committee members expressed a willingness to rein in its quantitative easing policies. The economy is still giving off mixed signals -- for example, housing's down sequentially, but up from the year-ago period -- and traders continue to look for the juice the Fed's policies provide.
With three-quarters of all stocks on the New York Stock Exchange falling yesterday, it's notable that the three companies below went in the other direction. But resist the urge to high-five everyone in the cubicles next to you. Smart investors won't celebrate until they know why their stock surged, because without a fundamental basis for the bounce, these stocks could just as quickly make the return trip down.
Allscripts Healthcare Solutions
Prescription for growth
The near-14% gain recorded by electronic medical records specialist Allscripts Healthcare Solutions seems like a bit of an anomaly. It reported fourth-quarter adjusted earnings of $0.16 per share compared to $0.25 a year ago, and analysts were anticipating adjusted profits of $0.20. On a GAAP basis it was even worse, swinging to $0.14 in per share loss from earnings of $0.14 per share in 2011, and revenues were down almost 10%. Doesn't seem like much to get excited about.
Yet it also said that bookings were surging, rising to $180.7 million from $161.9 million in the third quarter, which suggests the business may be gaining traction once again.
To say 2012 was a tumultuous one for Allscripts is a bit of an understatement. It ousted its board chairman last April for unspecified reasons, and three board members resigned in protest, along with the CFO who resigned to go somewhere else. Later in the year, the company announced it was considering selling itself, only to decide afterwards that it would be better off as a stand-alone company. Then it fired its CEO. Whew! Left hand, meet the right hand. You'd do well to know what the other one is doing.
So the fact it was gaining business despite an otherwise dismal performance suggests that the business itself isn't broken, but needed new management to guide it forward. Well, it certainly has that, doesn't it? With EMR a key component of President Obama's stimulus package a few years back, there are plenty of opportunities remaining for growth, and it's also possible that Allscripts remains a takeover candidate despite the company's recent decision to the contrary.
Sina's fourth-quarter results were incongruous with its price action much the way Allscripts were. Non-GAAP earnings came in at $0.13 per share, down from $0.21 last year, but also under analyst expectations. Revenues of $134 million missed forecasts as well, even though they were up more than 4% from the year-ago period.
What seems to have charged the Chinese online media company's stock, though, is its micro-blogging site, Weibo, which turned in a surprisingly strong performance. The site generated $66 million for all of 2012, 27% of which came from advertising. In the quarter, Weibo added $21.3 million in advertising revenues, or 10% more than it generated in the third quarter.
Yet it was also noted that rivals like Tencent continued to erode the amount of time people spent on Weibo. The WeChat application has gained in popularity, forcing Sina to focus more intently on the mobile space than it had previously. Although it experienced a slowdown in active user growth on Weibo in the fourth quarter, management still expects the user base to grow now that it has reached a "critical mass."
Carried over the threshold
It wasn't anything so exciting as what's going on at Allscripts that caused Threshold Pharmaceuticals to jump 11%, but analysts at Piper Jaffray are pretty stoked nonetheless about the potential of the biotech's experimental cancer drug TH-302 that they upgraded their outlook on its stock to "overweight" from "neutral." The move comes ahead of clinical trial data Threshold is preparing to report, and the analyst seems confident enough that he doubled his price target to $10 a share.
Threshold's stock is up almost 15% already in 2013 following its announcement last month that it had initiated phase 3 trials for TH-302 to treat pancreatic cancer. The biotech's leading drug candidate is being tested for several indications, but as the Fool's Brandy Betz notes, the pancreatic cancer tests are perhaps the key for it as it is being tested alongside Gemzar, a first-in-line treatment from Eli Lilly. TH-302 suffered a speed bump last fall when survival rates were insignificantly different from Gemzar, but it wasn't a fatal blow because that wasn't its primary endpoint.
The phase 3 trials it's currently undertaking will seek out improved survival rates, so that's what analysts will be closely monitoring. Achieving its goal will push the drug to the forefront, and with Merck KGaA paying its clinical trial bills, Threshold seems to runs little risk of running out of money. Piper Jaffray seems to believe it's already made it there.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more -- and get a full year of free updates -- click here to claim your copy today.
The article Whoa! These 3 Stocks Outmaneuvered the Dow originally appeared on Fool.com.
Fool contributor Rich Duprey has no position in any stocks mentioned. The Motley Fool recommends Sina. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.